Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.
We analyzed the role of antibiotic prophylaxis during decitabine treatment for MDS. The primary endpoint was the incidence of febrile episodes. The total number of decitabine cycles given to 28 patients was 131, and febrile episodes occurred in 15 cycles (11.5%). Antibiotic prophylaxis was orally administered in 95 cycles (72.5%). Febrile episodes were significantly less frequent among patients who received antibiotic prophylaxis (7.4%) than in those without prophylaxis (22.2%) (P=0.017). In conclusion, antibiotic prophylaxis reduced the incidence of febrile episodes in patients who received decitabine treatment for MDS, especially at earlier cycles and in the presence of severe cytopenia.
Lee
Je-Hwan
JH
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. jhlee3@amc.seoul.kr
Lee
Kyoo-Hyung
KH
Lee
Jung-Hee
JH
Kim
Dae-Young
DY
Kim
Sung-Han
SH
Lim
Sung-Nam
SN
Kim
Sung-Doo
SD
Choi
Yunsuk
Y
Lee
Sang-Min
SM
Lee
Won-Sik
WS
Choi
Moon-Young
MY
Joo
Young-Don
YD
D000328:Adult; D000368:Aged; D019072:Antibiotic Prophylaxis / Q000379:methods*; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D001064:Appendicitis / Q000139:chemically induced; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077209:Decitabine; D004334:Drug Administration Schedule; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000517:prevention & control*; D024841:Fluoroquinolones / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D013997:Time Factors; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D024841:Fluoroquinolones; D000077209:Decitabine; D001374:Azacitidine